BioPharmSignal logoBioPharmSignal

Biotech News

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon (XENE)XenonCompany update

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today

Related news

XENEXenon2026-07-30 20:01 EST

Xenon to Report Q2 2026 Financial Results on August 6, 2026

PRAXPraxis Precision Medicines2026-08-04 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-07-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-08-07 12:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-08-06 20:01 EST

Xenon Reports Q2 2026 Financial Results and Provides Business Update

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-08-06 20:01 EST

Xenon Reports Q2 2026 Financial Results and Provides Business Update

XENEXenon2026-07-31 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-07-30 20:01 EST

Xenon to Report Q2 2026 Financial Results on August 6, 2026

XENEXenon2026-07-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-05-29 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
64.55 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States